Baisong Mei

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

Baisong Mei, Clark Q. Pan, Haiyan Jiang et al. · Blood · 2010 · 229 citations · Full text

Lysophosphatidic Acid and Sphingosine 1-Phosphate Protection of T Cells from Apoptosis in Association with Suppression of Bax

Edward J. Goetzl, Yvonne Kong, Baisong Mei · The Journal of Immunology · 1999 · 218 citations · Full text

T-regulatory Cell, Apoptosis, Immunology +20

Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats

Christopher J. Parsons, Blair U. Bradford, Clark Q. Pan et al. · Hepatology · 2004 · 191 citations · Full text

Liver Fibrosis, Immunology, Pathology +24

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial

Guy Young, Alok Srivastava, Kaan Kavaklı et al. · The Lancet · 2023 · 105 citations

Treatment And Prevention, Randomised Phase 3, Fitusiran Prophylaxis +5

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice

Ekta Seth Chhabra, Tongyao Liu, John D. Kulman et al. · Blood · 2020 · 103 citations · Full text